Karmanos Cancer Institute MAIN MENU SECTION MENU Multiple Myeloma and Amyloidosis Program Karmanos Cancer InstituteMultidisciplinary TeamsMultiple Myeloma and Amyloidosis Program Clinical Trials To offer hope and longer life to patients with all types of cancer, Karmanos offers the latest types of therapy through our Clinical Trials Program. View Clinical Trials Multiple Myeloma and Amyloidosis Program If you’ve been diagnosed with the rare diseases of multiple myeloma or amyloidosis, it’s important to be evaluated by hematology experts before beginning treatment. We can help. Request an Appointment Online Call 1-800-KARMANOS What is Multiple Myeloma and Amyloidosis? Multiple myeloma is cancer of the plasma cells, a type of white blood cell that produces antibodies, which fight off infection. Multiple myeloma is more common in older adults and symptoms may include elevated calcium levels, kidney injury, anemia, painful bone lesions or recurrent infections. It is generally not curable, but there are many effective therapies available that can help people with this illness stay healthy longer. Amyloidosis is a group of diseases that have one thing in common: abnormal protein deposits in bodily tissues, with symptoms that depend on which organs are affected. The most important organs that may be injured by amyloidosis include the heart, kidneys, nerves and liver. One of the most common types of amyloidosis is called AL (immunoglobulin light chain) amyloidosis. Some patients with AL amyloidosis also have multiple myeloma. Therapy for AL amyloidosis is similar to that of multiple myeloma, though patients may have a difficult time tolerating therapy due to the symptoms they are experiencing as a result of the underlying amyloidosis. Diseases treated include: Amyloidosis Multiple Myeloma Karmanos’ Multiple Myeloma and Amyloidosis Specialists Our Multiple Myeloma and Amyloidosis Multidisciplinary Team sees between 230 and 250 new multiple myeloma patients and between 30 and 50 new amyloidosis patients each year. The team spans many disciplines, including hematologists, medical oncologists, specialized nurse practitioners, bone marrow transplant specialists, radiologists, pathologists, cardiologists, nephrologists, radiation oncologists, orthopedic surgeons, dietitians and social workers. The team is entirely focused on treating multiple myeloma and amyloidosis and shares its collective expertise to create a customized treatment plan for each patient. Our team of researchers not only has vast clinical expertise, but also years of clinical research experience. We have one of the largest myeloma bone marrow transplant programs in the country and are one of the few centers in the region offering investigational cellular therapies such as CAR-T cells to patients with Multiple Myeloma. In fact, Karmanos also has more active clinical trials for patients with multiple myeloma and amyloidosis than any other center in the state of Michigan. The team collaborates with basic scientists to better understand multiple myeloma and amyloidosis and to bring these new therapies to the clinic. Evaluation & Diagnosis Every new multiple myeloma or amyloidosis patient seen in consultation at Karmanos has his or her case reviewed in the weekly MDT meeting to facilitate a customized treatment plan and timely referral to the various subspecialists needed for optimal care. During your initial visit at a Karmanos location, a physician will review your medical records, medical history and review your x-rays and pathology slides. Innovative, Individualized Care Here’s what patients can expect from our Multiple Myeloma and Amyloidosis Multidisciplinary Team: A passionate, caring, expert team, giving you the best chance of success. A collaborative approach that considers all available treatment options, including clinical trials, for your specific type of cancer. A carefully constructed treatment plan designed to achieve the best possible outcome. Respectful, compassionate care that is responsive to your emotional needs and lifestyle. Proactive, timely communication with you and your loved ones, and your personal physician. Appointment Information Request an Appointment Online Request an Appointment By Phone Meet Our Multidisciplinary Team Multiple Myeloma and Amyloidosis Program - Team Lead - Multiple Myeloma and Amyloidosis - Jeffrey Zonder, M.D. Cardiology Luis Afonso, M.D. Anupama Kottam, M.D. Clinic/Research Nursing Angela Howey, RN Amy Huddlestun, BSN, RN, OCN Colleen Neveux, RN, CCRP Hematology & Medical Oncology Abhinav Deol, M.D. Andrew Kin, M.D. Jeffrey Zonder, M.D. Nephrology Nashat Imran, M.D. Nurse Practitioners Joe Ellul, DNP, AGNP-C Amy Skotzke, NP Orthopedic Oncology Alysia Kemp, M.D. Pathology Ali Mahdi Gabali, M.D., Ph.D. Radiation Oncology Harold Kim, M.D. Radiology Alit Amit-Yousif, M.D. Hussein Aoun, M.D. Sunil Bajaj, M.D. Agnieszka Choromanska, M.D. Jason Domina, M.D. Michael Petrich, M.D. Natasha Robinette, M.D. Nithin Thummala, M.D. Supportive Oncology Michael Stellini, M.D., M.S The Latest From Karmanos Cancer Institute News Videos Awards Podcasts NOVEMBER 19, 2021 Karmanos Cancer Institute receives multi-million dollar grant to determine why advanced cancer treatment fails African Americans The Barbara Ann Karmanos Cancer Institute and Wayne State University recently received a $2,997,215 federal grant to help determine why African Am... Read More NOVEMBER 17, 2021 Detroit Police Department uses pink patrol care to raise funds for Karmanos In October 2019, the red and blue lights on a Detroit Police Department cruiser were complemented by a new color: pink. The department outfitted o... Read More NOVEMBER 15, 2021 How a targeted lung cancer treatment available in Flint spares healthy organs and tissues from unnecessary radiation “Depending on the location and size of the tumor located in the lung, with the technology that we have at the McLaren Proton Therapy Center, we ca... Read More View All News About Karmanos Audience Navigator HEADQUARTERS Karmanos Cancer Institute 4100 John R Detroit, Michigan 48201 Contact Us © 2021 All rights reserved. McLaren Health Care and/or its related entity